On Thursday, Shares of Chicago Bridge & Iron Company N.V. (NYSE:CBI), lost -5.24% to $37.58.
Chicago Bridge & Iron Company, declared it has been awarded a contract valued at about $100 million by the U.S. Federal Government to provide fuel services at military installations around the world.
“This new contract underscores the exceptional service CB&I has offered to multiple government departments and agencies for more than 30 years,” said Chip Ray, President of CB&I’s Capital Services operating group. “We are proud to have been chosen to deliver these important fuel services, which support mission-critical operations worldwide.”
Chicago Bridge & Iron Company N.V. provides conceptual design, technology, engineering, procurement, fabrication, modularization, construction, commissioning, maintenance, program administration, and environmental services worldwide.
Shares of Allstate Corp (NYSE:ALL), declined -0.46% to $57.97, during its last trading session.
The Allstate Corporation, will conduct a conference call and webcast at 9 a.m. Eastern Time (ET) on Tuesday, November 3 to discuss third quarter 2015 earnings.
The company will file a current report on Form 8-K with the Securities and Exchange Commission announcing quarterly results at or after 4:15 p.m. ET on Monday, November 2. To view Allstate’s quarterly results counting the earnings release, investor supplement and quarterly Form 10-Q after their filing, please visit the SEC website at www.sec.gov. These materials will also be available by about 5 p.m. ET on Allstate’s website at www.allstateinvestors.com.
The Allstate Corporation, through its auxiliaries, engages in the property-liability insurance and life insurance businesses in the United States and Canada. The company’s Allstate Protection segment sells private passenger auto and homeowners insurance products under the Allstate, Encompass, Esurance brand names.
At the end of Thursday’s trade, Shares of BB&T Corporation (NYSE:BBT), gained 0.08% to $35.63.
BB&T IHC International Ltd., a partner of BB&T Corporation (BBT), declared it has reached a contract to enter into a partnership with Willis Group Holdings (WSH), the global risk advisor, re/insurance broking and human capital and benefits firm, and Miller Insurance Services LLP, a specialist wholesale insurance broker operating internationally and a top five Lloyd’s broker.
On June 1, 2015 , Willis declared that it had attained an 85 percent interest in the Miller partnership. Partners of Miller retain the remaining 15 percent interest which will be transferred to new generations of Miller partners in perpetuity. Willis’ acquisition of an 85 percent stake in Miller Insurance Services LLP was accomplished through Miller 2015 Limited, a partner of Willis established exclusively to house this partnership.
BB&T has agreed to acquire 19.9 percent of Miller 2015 Limited from Willis, resulting in a 16.9 percent interest in Miller Insurance Services LLP.
BB&T Corporation operates as a financial holding company that provides various banking and trust services for retail and commercial clients. It operates in six segments: Community Banking, Residential Mortgage Banking, Dealer Financial Services, Specialized Lending, Insurance Services, and Financial Services.
Finally, Amicus Therapeutics, Inc. (NASDAQ:FOLD), ended its last trade with -1.72% loss, and closed at $13.75.
Amicus Therapeutics, has successfully accomplished its formerly declared acquisition of 100% of the capital stock of Scioderm, Inc. a privately-held biopharmaceutical company focused on developing innovative therapies for treating diseases with high unmet need.
“The successful closing of the Scioderm acquisition is another important step forward toward fulfilling our patient-centric vision to build one of the world’s leading rare disease biotechnology companies,” said John F. Crowley, Chairman and Chief Executive Officer of Amicus. “We now have one of the industry’s leading pipelines of advanced therapies for devastating rare and orphan diseases. Within the next 12 months, we have the potential to have a marketed product for Fabry disease in the EU, marketing applications ready to submit for our investigational product for Epidermolysis Bullosa (EB) in the US and EU, and a Pompe program entering Phase 3 development. Recently we believe that Amicus is stronger than ever and has the potential to create noteworthynear- and long-term value for patients in addition to our shareholders.”
The acquisition of Scioderm strengthens Amicus’ pipeline significantly with the addition of a novel, late-stage, proprietary topical cream and potential first-to-market therapy for EB (SD-101). This investigational product was granted FDA breakthrough therapy designation in 2013 based on results from Phase 2 studies for the treatment of lesions in patients suffering with EB. SD-101 is presently being investigated in a Phase 3 study to support global regulatory submissions and was the first-ever treatment in EB clinical studies to show improvements in wound closure across all major EB subtypes.
Amicus Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapeutic products for rare and orphan diseases. Its product candidate is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.